These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17726337)

  • 1. Lesson learned from Eprex-associated pure red cell aplasia.
    Schellekens H
    Kidney Blood Press Res; 2007; 30 Suppl 1():9-12. PubMed ID: 17726337
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pure red blood cell aplasia associated with neutralizing antibodies against erythropoietin induced by epoetin alfa:a new form of acquired erythroblastopenia in auremic patients].
    Cases A; Esforzado N; Mas M; Ricart MJ; Cruzado JM
    Nefrologia; 2003; 23(3):266-70. PubMed ID: 12891943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pure red-cell aplasia and epoetin therapy.
    Bennett CL; Luminari S; Nissenson AR; Tallman MS; Klinge SA; McWilliams N; McKoy JM; Kim B; Lyons EA; Trifilio SM; Raisch DW; Evens AM; Kuzel TM; Schumock GT; Belknap SM; Locatelli F; Rossert J; Casadevall N
    N Engl J Med; 2004 Sep; 351(14):1403-8. PubMed ID: 15459301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epoetin alfa (Eprex): reports of pure red blood cell aplasia.
    Wooltorton E
    CMAJ; 2002 Feb; 166(4):480. PubMed ID: 11873930
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug-induced autoimmune red-cell aplasia.
    Bunn HF
    N Engl J Med; 2002 Feb; 346(7):522-3. PubMed ID: 11844855
    [No Abstract]   [Full Text] [Related]  

  • 6. Reactions to Eprex's adverse reactions.
    Sharma B; Ryan MH; Boven K
    Nat Biotechnol; 2006 Oct; 24(10):1199-200; author reply 1200. PubMed ID: 17033648
    [No Abstract]   [Full Text] [Related]  

  • 7. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.
    Macdougall IC
    Curr Med Res Opin; 2004 Jan; 20(1):83-6. PubMed ID: 14741076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eprex-associated pure red cell aplasia and leachates.
    Schellekens H; Jiskoot W
    Nat Biotechnol; 2006 Jun; 24(6):613-4. PubMed ID: 16763579
    [No Abstract]   [Full Text] [Related]  

  • 9. Pure red-cell aplasia secondary to antierythropoietin antibodies.
    Guest SS; Levitt L
    N Engl J Med; 2003 Dec; 349(26):2572-3. PubMed ID: 14695426
    [No Abstract]   [Full Text] [Related]  

  • 10. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
    Casadevall N; Nataf J; Viron B; Kolta A; Kiladjian JJ; Martin-Dupont P; Michaud P; Papo T; Ugo V; Teyssandier I; Varet B; Mayeux P
    N Engl J Med; 2002 Feb; 346(7):469-75. PubMed ID: 11844847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two haemodialysis patients with epoetin alfa-induced pure red-cell aplasia recovered despite treatment with another epoetin preparation.
    Vartia A; Asola MR; Tertti R; Kunelius P; Metsärinne KP
    Nephrol Dial Transplant; 2004 May; 19(5):1313-6. PubMed ID: 15102972
    [No Abstract]   [Full Text] [Related]  

  • 12. [Unusual but serious adverse effect. Epoetin treatment of patients with kidney diseases caused erythroblastopenia].
    Stenvinkel P; Bárány P
    Lakartidningen; 2002 Oct; 99(42):4162-3. PubMed ID: 12448296
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pure red cell aplasia developed during treatment with erythropoietin. Complete remission during immunosuppressive therapy].
    Høi-Hansen T; Lauritzen AM; Hansen PB
    Ugeskr Laeger; 2003 May; 165(19):2001-2. PubMed ID: 12795077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on reintroduction of epoetin in a patient with pure red call aplasia.
    Campbell N; Krishnakumar S; Matijevic A; Almond M
    Nephrol Dial Transplant; 2008 Oct; 23(10):3365. PubMed ID: 18567693
    [No Abstract]   [Full Text] [Related]  

  • 15. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS).
    Macdougall IC; Casadevall N; Locatelli F; Combe C; London GM; Di Paolo S; Kribben A; Fliser D; Messner H; McNeil J; Stevens P; Santoro A; De Francisco AL; Percheson P; Potamianou A; Foucher A; Fife D; Mérit V; Vercammen E;
    Nephrol Dial Transplant; 2015 Mar; 30(3):451-60. PubMed ID: 25239637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done?
    Macdougall IC; Roche A; Rossert J; Casadevall N; Francois P; Kemeny DM
    Nephrol Dial Transplant; 2004 Nov; 19(11):2901-5. PubMed ID: 15496566
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pure red cell aplasia and antibodies against erythropoietin. Doubts still remain].
    Peces R
    Nefrologia; 2003; 23(4):295-6, 297. PubMed ID: 14558327
    [No Abstract]   [Full Text] [Related]  

  • 18. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia.
    Casadevall N; Cournoyer D; Marsh J; Messner H; Pallister C; Parker-Williams J; Rossert J
    Eur J Haematol; 2004 Dec; 73(6):389-96. PubMed ID: 15522059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epoetin-induced autoimmune pure red cell aplasia.
    Casadevall N
    Hematol J; 2004; 5 Suppl 3():S104-9. PubMed ID: 15190289
    [No Abstract]   [Full Text] [Related]  

  • 20. Epoetin-induced pure red cell aplasia: diagnosis and treatment.
    Macdougall IC
    Curr Opin Nephrol Hypertens; 2007 Nov; 16(6):585-8. PubMed ID: 18089975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.